Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire initiates European launch of Dynepo

Shire initiates European launch of Dynepo

16th March 2007

Shire has announced the launch of anaemia treatment Dynepo (epoetin delta) in Germany, starting the roll-out programme for the compound across Europe. The compound will be launched in other European countries in forthcoming months.

The compound aims to provide a choice to patients suffering from anaemia as a result of chronic renal failure and is approved in patients with end-stage renal disease undergoing dialysis treatment in addition to those who do not yet require dialysis.

Dynepo is an erythropoiesis-stimulating agent (ESA) made in human cells that can be administered subcutaneously or intravenously. Erythropoietin is a glycoprotein hormone that contains carbohydrate residues important to the body.

Mike Cola, president of speciality pharmaceuticals at Shire, said: “Dynepo’s unique human gene activation origin and comprehensive clinical efficacy and safety programme provide physicians with an alternative choice in the management of anaemia.”

He added that the company had developed pricing structures for the compounds to lower costs consumed by ESA treatments and the price of treating renal anaemia.

In October 2006, Shire reported the publication of the results of a two-year trial in Kidney International showing that Fosrenol (lanthanum carbonate) does not impact on deterioration of cognitive function in chronic kidney disease patients with hyperphosphatemia.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.